X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
CMND-100 (5-methoxy-2-aminoindane) is a MEAI-based psychedelic-derived drug candidate which is being investigated for the treatment of Alcohol Use Disorder. MEAI breaks the vicious binge-drinking cycle by innervating 5-HT1A neural pathways.
Lead Product(s): 5-Methoxy-2-Aminoindane
Therapeutic Area: Psychiatry/Psychology Product Name: CMND-100
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 13, 2024
Details:
CMND-100 (5-methoxy-2-aminoindane) is a MEAI-based psychedelic-derived drug candidate which is being investigated for the treatment of Alcohol Use Disorder. MEAI breaks the vicious binge-drinking cycle by innervating 5-HT1A neural pathways.
Lead Product(s): 5-Methoxy-2-Aminoindane
Therapeutic Area: Psychiatry/Psychology Product Name: CMND-100
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 23, 2024
Details:
Under the agreement, Clearmind will use the joint patent it has with BIRAD for innovative cocaine treatment using CMND-100 (5-methoxy-2-aminoindane), its novel psychedelic molecule.
Lead Product(s): 5-Methoxy-2-Aminoindane
Therapeutic Area: Psychiatry/Psychology Product Name: CMND-100
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: BIRAD
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement February 01, 2024
Details:
CMND-100 (5-methoxy-2-aminoindane) is a MEAI-based psychedelic-derived drug candidate which is being investigated for the treatment of Alcohol Use Disorder. MEAI breaks the vicious binge-drinking cycle by innervating 5-HT1A neural pathways.
Lead Product(s): 5-Methoxy-2-Aminoindane
Therapeutic Area: Psychiatry/Psychology Product Name: CMND-100
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 10, 2024
Details:
The combination treatment includes palmitoylethanolamide (PEA), an anti-inflammatory agent and the active ingredient of the Company’s proprietary CannAmide, and MEAI, Clearmind’s novel proprietary psychedelic treatment for various addictions, obesity, and depression.
Lead Product(s): Palmitoylethanolamide,5-Methoxy-2-Aminoindane
Therapeutic Area: Nutrition and Weight Loss Product Name: SCI-210
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: SciSparc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 01, 2023
Details:
CMND-100 (5-methoxy-2-aminoindane) is a MEAI-based psychedelic-derived drug candidate which is being investigated for the treatment of Alcohol Use Disorder. MEAI breaks the vicious binge-drinking cycle by innervating 5-HT1A neural pathways.
Lead Product(s): 5-Methoxy-2-Aminoindane,Palmitoylethanolamide
Therapeutic Area: Nutrition and Weight Loss Product Name: CMND-100
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 28, 2023
Details:
CMND-100 (5-methoxy-2-aminoindane) is a MEAI-based psychedelic-derived drug candidate which is being investigated for the treatment of Alcohol Use Disorder. MEAI breaks the vicious binge-drinking cycle by innervating 5-HT1A neural pathways.
Lead Product(s): 5-Methoxy-2-Aminoindane
Therapeutic Area: Psychiatry/Psychology Product Name: CMND-100
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2023
Details:
The Company will use the proceeds for clinical and pre-clinical testing of company's product candidates, including MEAI (5-methoxy-2-aminoindane), a novel psychoactive molecule which reduce the desire to consume alcoholic beverages.
Lead Product(s): 5-Methoxy-2-Aminoindane
Therapeutic Area: Nutrition and Weight Loss Product Name: MEAI
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Aegis Capital Corp.
Deal Size: $2.2 million Upfront Cash: Undisclosed
Deal Type: Public Offering September 18, 2023
Details:
The Company will use the proceeds for clinical and pre-clinical testing of company's product candidates, including MEAI (5-methoxy-2-aminoindane), a novel psychoactive molecule which reduce the desire to consume alcoholic beverages.
Lead Product(s): 5-Methoxy-2-Aminoindane
Therapeutic Area: Nutrition and Weight Loss Product Name: MEAI
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Aegis Capital Corp.
Deal Size: $2.2 million Upfront Cash: Undisclosed
Deal Type: Public Offering September 14, 2023
Details:
The agreement aims to conduct its Phase I/IIa clinical trial of its proprietary MEAI-based CMND-100, a novel psychedelic-derived drug candidate, to treat Alcohol Use Disorder.
Lead Product(s): 5-Methoxy-2-Aminoindane
Therapeutic Area: Psychiatry/Psychology Product Name: CMND-100
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Johns Hopkins University
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement September 06, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
